Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Gentzler on the Role of Chemotherapy in Metastatic NSCLC

August 21st 2018

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses the role of chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC).

Lead Investigator Discusses Pegilodecakin/PD-1 Inhibitor Combination in NSCLC

August 21st 2018

Edward B. Garon, MD, discusseds early findings with pegilodecakin in non–small cell lung cancer.

Dr. Gandara on Treatment Options for Squamous Cell NSCLC

August 20th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, 2017 Giant of Cancer Care in Lung Cancer, discusses treatment options for patients with squamous cell non–small cell lung cancer.

FDA Grants Full Approval to Pembrolizumab Plus Chemo for NSCLC

August 20th 2018

The FDA has granted a full approval to frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.

Neoadjuvant Immunotherapy Emerges as a New Frontier

August 20th 2018

Although checkpoint blocking immunotherapy has significantly improved outcomes for patients with advanced and metastatic disease, researchers believe the modality also may be effective in the neoadjuvant setting.

Dr. Borghaei on the FDA Approval of Nivolumab in Small Cell Lung Cancer

August 17th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the FDA approval of nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

FDA Approves Nivolumab for Small Cell Lung Cancer

August 17th 2018

The FDA has approved single-agent nivolumab for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

Dr. Papadimitrakopoulou on Importance of More Targeted Therapies in NSCLC

August 16th 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the need for more targeted therapies in non–small cell lung cancer.

Updates Continue in Oncogene-Driven Lung Cancer

August 16th 2018

Jose M. Pacheco, MD, discusses the preferred therapeutic strategies for treating patients with NSCLC whose tumors harbor genetic alterations in EGFR, ALK, and ROS1.

Drilon Discusses Promise of LOXO-292 in RET-Altered Solid Tumors

August 16th 2018

Alexander E. Drilon, MD, discusses the data with LOXO-292 thus far and the promise for this agent in patients with RET alterations.

Dr. Bunn on TMB as a Biomarker in Small Cell Lung Cancer

August 15th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses tumor mutational burden as a biomarker in small cell lung cancer.

Expert Explains Work Needed for Immunotherapy/RT Approaches in NSCLC

August 15th 2018

James Larner, MD, discusses the process by which radiation interacts with the immune system and how physicians are working to improve treatment responses for patients with non–small cell lung cancer.

Dr. Feliciano on ROS1-Targeted Therapy in NSCLC

August 15th 2018

Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses ROS1-targeted therapy in patients with non–small cell lung cancer (NSCLC).

Immunotherapy Data Lead Lung Cancer Landscape Following ASCO 2018

August 15th 2018

Apar Kishor Ganti, MD, discusses some of the most intriguing abstracts in lung cancer recently presented at medical meetings.

Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLC

August 14th 2018

James Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).

Standards of Care Shifting in Early-Stage NSCLC

August 14th 2018

Alexander R. Menter, MD, discusses treatment advances in early-stage non–small cell lung cancer (NSCLC).

Dr. Liu on Resistance Mechanisms in EGFR-Mutant Lung Cancer

August 14th 2018

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses resistance mechanisms in EGFR-mutant lung cancer.

Dr. Walters on the Best Approach to Treating Patients With Stage III Lung Cancer

August 13th 2018

Dustin M. Walters, MD, assistant professor, Thoracic and Cardiovascular Surgery, University of Virginia Health System, discusses the best approach to treating patients with stage III lung cancer.

Dr. Falchook on TRK Alterations in Lung Cancer

August 13th 2018

Gerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses TRK alterations in lung cancer.

Mok Discusses Dacomitinib Potency in Frontline EGFR+ NSCLC

August 13th 2018

Tony Mok, MD, discusses the promise of dacomitinib for the frontline treatment of patients with EGFR-mutant NSCLC.